Chronic Kidney Disease Trial, Recruiting NCT02986984 Sponsor: University of Pennsylvania Condition: Chronic Kidney Disease
Back to Chronic Kidney Disease

Chronic Kidney Disease Trial, Recruiting

NCT02986984
Recruiting Not Applicable

Who may be able to join

AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI

Who might be able to join this trial:

  • People who have been diagnosed with Type 1 or Type 2 diabetes, according to American Diabetes Association standards.
  • People who are willing to follow the study's requirements, including attending follow-up appointments at a clinical study site as outlined in the study plan.
  • People who are able to understand and sign a consent form agreeing to take part in the study.
  • Adults (18 years of age or older).
  • People who have already been scheduled for a kidney biopsy by a kidney specialist (nephrologist) for medical reasons.

Who may not be able to join:

  • People who have end-stage kidney disease, meaning those currently on ongoing dialysis or who have received a kidney transplant.
  • People who have been on dialysis for more than 30 days before the kidney biopsy.
  • People who are currently living in an institution (such as a care facility or prison).
  • People who have received a transplant of a solid organ or bone marrow at the time of their first kidney biopsy.
  • People who are not expected to live for at least 3 more years.
  • People with a current or recent serious alcohol or drug misuse problem that, in the opinion of the study doctor, may affect their ability to follow the study requirements.
  • People who are unable to understand or sign a consent form.
  • People who are currently being treated for active cancer, with the exception of a common and less serious type of skin cancer called non-melanoma skin cancer.

Important: Always verify eligibility with the trial site directly before applying.

Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.

This is a simplified plain English summary of the eligibility criteria. Full criteria are set by the trial investigators and may include additional requirements not shown here. Never self-exclude from a trial based on this summary. Contact the trial site directly to confirm your eligibility.
Last synced 28 July 2026
This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.

Contact this trial

Principal Investigator: Katalin Susztak, MD, University of Pennsylvania

Phone: 646-541-4079

Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.

GP referral letter

Print a one-page summary to share with your doctor.

Trial details

Status
Recruiting
Phase
Not Applicable
Registry
ClinicalTrials.gov
Start date
1 December 2016
Est. completion
1 June 2027

Where this trial is recruiting

🇺🇸 United States

Primary endpoints

Rapid progression of kidney function loss

Can't join this trial?

Expanded access pathways

If this trial is not available to you, other access pathways may exist. In Australia, the TGA Special Access Scheme allows access to unapproved therapeutic goods for individual patients.

TGA Special Access Scheme information

Find other recruiting trials on ClinicalTrials.gov

Data last synced from ClinicalTrials.gov: 28 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.

Trial recruitment status can change without notice between our nightly data updates. Always contact the trial site directly to confirm current recruitment status before making any decisions or travel arrangements.

View original record on ClinicalTrials.gov